Would you re-test oral semaglutide after ten weeks at 25 °C, or accept the original certificate?

The particulars: oral semaglutide · ten weeks · 25 °C.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

How do I make this decision on evidence rather than on feel?

ten weeks is 70 days, and at 25 °C the ten-degree rule of thumb makes that roughly 280 refrigerated days of equivalent exposure. 25 °C is 20 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 4 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. Compare that against what the certificate covers, which is the material as it left the laboratory on the date of analysis and nothing after it. 280 equivalent days is past the point where the original figure is evidence about the current vial, so the honest answer is that you no longer have a certificate for what you are holding. If you do re-test, send it for content as well as purity; the 70 days will have moved one of them further than the other.

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

What each test answers

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

Assume segregation is possible, and design your sampling to catch it if it exists.

More usefully, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Specifically, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

edited 20 Jun 2026 by kwn_analytical — removed a claim I could not source

Stated carefully, two vials tested from a lot of ten is very different from two vials tested from a lot of ten thousand, and most certificates do not state the lot size.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Specifically, if a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.